STOCK COMPARISON
Veracyte vs Thermo Fisher Scientific: Fair Value & Quality
Both stocks run through our valuation models. Here is how Veracyte (VCYT) and Thermo Fisher Scientific (TMO) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Veracyte trades at $47.22 versus a fair value of $18.29 (-61%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).
Veracyte
VCYT · USD · Health Care
-61%
upside to fair value
overvalued
Price$47.22
Fair Value$18.29
Quality71/100
Thermo Fisher Scientific
TMO · USD · Health Care
-48%
upside to fair value
overvalued
Price$594
Fair Value$308
Quality63/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
VeracyteThermo Fisher Scientific
Valuation
53.4×P/E (TTM)29.5×
8.34×P/S (TTM)4.41×
3.45×P/B3.74×
39.9×EV/EBITDA20.0×
—PEG1.74×
—Dividend yield0.3%
—Dividend per share$1.76
Profitability
16%Net margin15%
16%Operating margin18%
7%Return on equity14%
4%Return on assets5%
Growth
22%Revenue growth (YoY)6%
20.4%Avg. growth/yr (3Y)-0.3%
34.5%Avg. growth/yr (5Y)6.7%
Balance & size
0.00×Debt / equity0.67×
$5BMarket cap$199B
healthyGrowth qualityhealthy
Even match: 6 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Veracyteof which business quality 73 · market factors 61
Thermo Fisher Scientificof which business quality 60 · market factors 65
ProfitabilityMargins and returns on capital today
39
43
Quality GrowthAre margins and returns improving?
78
31
CashflowEarnings quality: real cash, not paper profit
96
62
Fin. StrengthBalance sheet, leverage, solvency risk
97
60
InvestmentDisciplined investing over empire-building
77
79
Low VolatilityCalm price path (market factor)
0
68
MomentumPrice trend over the last 3–12 months (market factor)
90
58
52W MomentumDistance to the 52-week high (market factor)
82
72
Net IssuanceBuybacks instead of dilution
45
97
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Veracyte
DCF Models$38.92
Earnings-Based$24.27
Dividend Discount$0.65
Multiples$17.45
Asset-Based$11.00
Growth DCF$38.45
Economic Profit$12.82
Growth Earnings$30.52
26 of 26 models see the stock below the current price.
Thermo Fisher Scientific
DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341
24 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Veracyte
Bear $13.72Fair Value $18.29Bull $22.87
$47.22 = current price (white tick)
Thermo Fisher Scientific
Bear $175Fair Value $308Bull $385
$594 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Veracyte · Health Care
Quality score71 · Top 25%
Fair value upside-61% · below median
Thermo Fisher Scientific · Health Care
Quality score63 · above median
Fair value upside-48% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Veracyte trades at $47.22 versus a fair value of $18.29 (-61%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).
Veracyte has the higher quality score (71/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
